Howard Bregman
Affiliations: | 2003-2007 | University of Pennsylvania, Philadelphia, PA, United States |
Google:
"Howard Bregman"Mean distance: (not calculated yet)
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Weiss MM, Dineen TA, Marx IE, et al. (2017) Sulfonamides as Selective NaV1.7 Inhibitors: Optimizing Potency and Pharmacokinetics While Mitigating Metabolic Liabilities. Journal of Medicinal Chemistry |
| Huang H, Guzman-Perez A, Acquaviva L, et al. (2013) Structure-based design of 2-aminopyridine oxazolidinones as potent and selective tankyrase inhibitors. Acs Medicinal Chemistry Letters. 4: 1218-23 |
| Hua Z, Bregman H, Buchanan JL, et al. (2013) Development of novel dual binders as potent, selective, and orally bioavailable tankyrase inhibitors. Journal of Medicinal Chemistry. 56: 10003-15 |
| Bregman H, Chakka N, Guzman-Perez A, et al. (2013) Discovery of novel, induced-pocket binding oxazolidinones as potent, selective, and orally bioavailable tankyrase inhibitors. Journal of Medicinal Chemistry. 56: 4320-42 |
| Bregman H, Gunaydin H, Gu Y, et al. (2013) Discovery of a class of novel tankyrase inhibitors that bind to both the nicotinamide pocket and the induced pocket. Journal of Medicinal Chemistry. 56: 1341-5 |
| Huang H, Acquaviva L, Berry V, et al. (2012) Structure-Based Design of Potent and Selective CK1γ Inhibitors. Acs Medicinal Chemistry Letters. 3: 1059-64 |
| Hua Z, Huang X, Bregman H, et al. (2012) 2-Phenylamino-6-cyano-1H-benzimidazole-based isoform selective casein kinase 1 gamma (CK1γ) inhibitors. Bioorganic & Medicinal Chemistry Letters. 22: 5392-5 |
| Pagano N, Wong EY, Breiding T, et al. (2009) From imide to lactam metallo-pyridocarbazoles: distinct scaffolds for the design of selective protein kinase inhibitors. The Journal of Organic Chemistry. 74: 8997-9009 |
| Bullock AN, Russo S, Amos A, et al. (2009) Crystal structure of the PIM2 kinase in complex with an organoruthenium inhibitor. Plos One. 4: e7112 |
| Xie P, Streu C, Qin J, et al. (2009) The crystal structure of BRAF in complex with an organoruthenium inhibitor reveals a mechanism for inhibition of an active form of BRAF kinase. Biochemistry. 48: 5187-98 |